Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2014

View Archived Issues

Janssen Therapeutics collaborates with USAID on multidrug-resistant TB initiative

Innate Immunotherapeutics expands compassionate use access to MS drug MIS-416

Pfizer initiates phase I trial of PF-06700841 in healthy adults and adults with plaque psoriasis

Inhibition of hydrogen sulfide gas production reduces chemotherapy-induced neuropathic pain

Arrest or reversion of liver disease by dual FXR/TGR5 agonist INT-767 in preclinical models

Alcon Research begins phase III trial of RTH-258

Novel anti-PD-L1/IL-15 fusion protein enhances immunological activity against tumor cells

OPKO Health and Pfizer enter into global agreement for hGH-CTP

Activity of fully human bispecific antibody against B-cell lymphoma described

FDA grants orphan drug status to ataluren for mucopolysaccharidosis type I

Galapagos regains rights to GLPG-1205

Allergan patent details novel EP2 receptor agonists for ocular diseases

Edison Pharmaceuticals develops compounds for oxidative stress disorders

Bristol-Myers Squibb researchers prepare MGAT2 inhibitors

XuanZhu Pharma patent divulges novel ALK inhibitors for cancer

Hinova Pharmaceuticals patents new AR antagonists

Cushing's syndrome treatment Ketoconazole HRA receives European marketing authorization

Ablynx initiates phase IIa trial of ALX-0171 in infants with RSV infection

FDA approves Ipsen's lanreotide depot for pancreatic and gastrointestinal neuroendocrine tumors

CSL Behring submits BLA to FDA for rIX-FP

Irisin identified as a biomarker for heart failure prognosis

Topline data from Auspex's First-HD study of SD-809

ADMA Biologics receives milestone payment for achievement of RI-002 clinical endpoints

Kymab to lead Wellcome Trust-funded Ebola virus consortium

FDA gives clearance to diaDexus Lp-PLA2 test for risk of coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...